WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 4 fonti

ASCO26: In vivo oncology approaches continue to show promise

Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.

Raccontata da

pharmaceutical-technology.com

biopharmadive.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.news1 mesi fa

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries

Leggi questa versione → originale

pharmaceutical-technology.com

Timeline cronologica

lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

1 mesi fa

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical…

Akeso's ivonescimab bispecific achieved 34% death risk reduction in squamous NSCLC; Eli Lilly expanded Retevmo (RET TKI) to adjuvant early-stage disease. Both mark competitive reshaping of NSCLC, with Idafang projected at $11bn global sales by 2032.

Leggi questa versione → originale

biopharmadive.com1 mesi fa

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Leggi questa versione → originale

statnews.com1 mesi fa

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

Leggi questa versione → originale

lunedì 1 giugno 2026·

statnews.com

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

lunedì 1 giugno 2026·

pharmaceutical-technology.com

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.

lunedì 1 giugno 2026·

endpoints.news

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries

martedì 2 giugno 2026·

biopharmadive.com

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

martedì 2 giugno 2026·

pharmaceutical-technology.com

ASCO26: In vivo oncology approaches continue to show promise

Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.

martedì 2 giugno 2026·

pharmaceutical-technology.com

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma - Pharmaceutical Technology

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.

mercoledì 3 giugno 2026·

pharmaceutical-technology.com

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.